Precision Biosciences (DTIL) Cash from Financing Activities (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of Cash from Financing Activities data on file, last reported at $745000.0 in Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 93.03% year-over-year to $745000.0 in Q1 2026; TTM through Mar 2026 was $85.2 million, a 305.0% increase from a year earlier, with the FY2025 full-year figure at $95.2 million, up 88.63% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $745000.0, down from $77.5 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for DTIL reached as high as $92.9 million in Q2 2022 and fell as low as -$180000.0 in Q3 2022.
• Historically, Cash from Financing Activities has averaged $15.4 million across 5 years, with a median of $2.5 million in 2022.
• Across the five-year window, Cash from Financing Activities slumped 101.51% in 2022 and soared 11079.41% in 2024, its largest moves.
• Year by year, Cash from Financing Activities stood at -$180000.0 in 2022, then soared by 1671.11% to $2.8 million in 2023, then soared by 109.34% to $5.9 million in 2024, then surged by 1209.39% to $77.5 million in 2025, then plunged by 99.04% to $745000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $745000.0 in Q1 2026, $77.5 million in Q4 2025, and $1.7 million in Q3 2025.